Home › Research › Biomarkers
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease
Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, Saef B, Chen CD et al.. Nature medicine, 2023-07-13
Topic: Brain proteins, microglia and lab models
Plain-language summary
Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because clinical symptoms are strongly correlated with tau aggregates, drug development and clinical diagnosis need cost-effective and accessible specific fluid biomarkers of tau aggregates; however, recent studies suggest that the fluid biomarkers currently available cannot specifically track tau aggregates. We show that the microtubule-binding region (MTBR) of tau containing the residue 243 (MTBR-tau243) is a new cerebrospinal fluid (CSF) biomarker specific for insoluble tau aggregates and compared it to multiple other phosphorylated tau measures (p-tau181, p-tau205, p-tau217 and p-tau231) in two independent cohorts (BioFINDER-2, n = 448; and Knight Alzheimer Disease Research Center, n = 219). MTBR-tau243 was most strongly associated with tau-positron emission tomography (PET) and cognition, whereas showing the lowest association with amyloid-PET. In combination with p-tau205, MTBR-tau243 explained most of the total variance in tau-PET burden (0.58 ≤ R 2 ≤ 0.75) and the performance in predicting cognitive measures (0.34 ≤ R 2 ≤ 0.48) approached that of tau-PET (0.44 ≤ R 2 ≤ 0.52). MTBR-tau243 levels longitudinally increased with insoluble tau aggregates, unlike CSF p-tau species. CSF MTBR-tau243 is a specific biomarker of tau aggregate pathology, which may be utilized in interventional trials and in the diagnosis of patients. Based on these findings, we propose to revise the A/T/(N) criteria to include MTBR-tau243 as representing insoluble tau aggregates ('T').
What this study adds
Evidence grade: Low
The record lists 448 participants. CSF MTBR-tau243 was most strongly associated with tau PET and cognition and least with amyloid PET, and in combination with p-tau205 explained most of the variance in tau PET burden. Its stated limit: This is based on two specific research cohorts (BioFINDER-2 and Knight ADRC) using spinal fluid samples; the abstract doesn't describe how the marker performs in more diverse, real-world clinical settings outside these study cohorts.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., et al. (2023). CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nature medicine. https://doi.org/10.1038/s41591-023-02443-z
Vancouver
Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nature medicine. 2023. doi:10.1038/s41591-023-02443-z. PMID: 37443334.
BibTeX
@article{horie2023-37443334,
author = {Horie, K. and Salvadó, G. and Barthélemy, N. R. and Janelidze, S. and Li, Y. and He, Y. and Saef, B. and Chen, C. D. and others},
title = {{CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease}},
journal = {Nature medicine},
year = {2023},
doi = {10.1038/s41591-023-02443-z},
pmid = {37443334},
url = {https://doi.org/10.1038/s41591-023-02443-z}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Because clinical symptoms are strongly correlated with tau aggregates, drug development and clinical diagnosis need cost-effective and accessible specific fluid biomarkers of tau aggregates; however, recent studies suggest that the fluid biomarkers currently available cannot specifically track tau aggregates.
- MTBR-tau243 was most strongly associated with tau-positron emission tomography (PET) and cognition, whereas showing the lowest association with amyloid-PET.
- Based on these findings, we propose to revise the A/T/(N) criteria to include MTBR-tau243 as representing insoluble tau aggregates ('T').
Why it matters
CSF MTBR-tau243 was most strongly associated with tau PET and cognition and least with amyloid PET, and in combination with p-tau205 explained most of the variance in tau PET burden. The authors propose it as a specific biomarker of tau aggregate pathology that may be used in interventional trials, but it is not itself a treatment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants448
- Evidence strengthLow
Limitations
This is based on two specific research cohorts (BioFINDER-2 and Knight ADRC) using spinal fluid samples; the abstract doesn't describe how the marker performs in more diverse, real-world clinical settings outside these study cohorts.
How this study scored 67/100
Published in a top-tier journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature medicine) |
| Journal's citation record | 4 / 4 | Nature Medicine: journal h-index 763 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 448 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 250 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 50.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 5 / 6 | Cited 36.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 25 other studies in this library |
| Still being cited | 4 / 4 | Cited 233 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Randall John Bateman: h-index 101 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37443334) |
| Free to read | 2 / 2 | Free to read |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 33.
Later studies that cite this one
25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.